Overview

A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants

Status:
Completed
Trial end date:
2017-07-05
Target enrollment:
Participant gender:
Summary
This study evaluated the safety and tolerability of single and multiple doses (400 and 800 milligrams [mg]) of ALXN1210 following intravenous administration to healthy Japanese participants.
Phase:
Phase 1
Details
Lead Sponsor:
Alexion Pharmaceuticals
Treatments:
Ravulizumab